Clinical trial
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
NCT01518244 is registered in ClinicalTrials.gov with Alcon Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
- Lead sponsor
- Alcon Research
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- February 28, 2013
- Enrollment
- 50 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.